https://www.mynewsdesk.com/se/astrazeneca/pressreleases Mynewsdesk nyhetsfeed direkt från källan https://www.mynewsdesk.com/se/astrazeneca/pressreleases https://www.mynewsdesk.com/assets/graphics/logos/logo-small-3b24ab90.png 128 23 sv 15 Wed, 31 May 2023 13:26:34 +0200 Från och med den 1 juni kommer AstraZeneca att upphöra med att skicka ut pressmeddelanden från Mynewsdesk. I stället kommer Cision att användas exklusivt som kanal för pressmeddelandeutskick. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-oevergaar-till-exklusiv-anvaendning-av-cision-foer-pressmeddelandeutskick-3256350?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-oevergaar-till-exklusiv-anvaendning-av-cision-foer-pressmeddelandeutskick-3256350?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Fri, 26 May 2023 08:06:32 +0200 Ultomiris (ravulizumab) has been approved in Japan as the first and only long-acting C5 complement inhibitor for the prevention of relapses in patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD), including neuromyelitis optica. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-neuromyelitis-optica-spectrum-disorder-nmosd-3255312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-approved-in-japan-for-the-prevention-of-relapses-in-patients-with-neuromyelitis-optica-spectrum-disorder-nmosd-3255312?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Fri, 26 May 2023 08:01:17 +0200 Positive high-level results from the DUO-E Phase III trial showed Imfinzi (durvalumab) in combination with platinum-based chemotherapy followed by either Imfinzi plus Lynparza (olaparib) or Imfinzi alone as maintenance therapy both demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy alone in... https://www.mynewsdesk.com/se/astrazeneca/pressreleases/imfinzi-plus-lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-advanced-endometrial-cancer-when-added-to-chemotherapy-3255344?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/imfinzi-plus-lynparza-and-imfinzi-alone-both-significantly-improved-progression-free-survival-in-advanced-endometrial-cancer-when-added-to-chemotherapy-3255344?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Thu, 25 May 2023 08:01:23 +0200 AstraZeneca advances its ambition to revolutionise cancer care with new data across its industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, 2 to 6 June 2023. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023-3255004?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-will-highlight-momentum-of-practice-changing-cancer-medicines-across-its-robust-pipeline-at-asco-2023-3255004?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Wed, 17 May 2023 08:02:12 +0200 Positive high-level results from the FLAURA2 Phase III trial showed Tagrisso in combination with chemotherapy demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to Tagrisso alone for patients with locally advanced (Stage IIIB-IIIC) or metastatic (Stage IV) epidermal growth factor receptor-mutated non-small cell lung cancer. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/tagrisso-plus-chemotherapy-demonstrated-strong-improvement-in-progression-free-survival-for-patients-with-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial-3253391?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/tagrisso-plus-chemotherapy-demonstrated-strong-improvement-in-progression-free-survival-for-patients-with-egfr-mutated-advanced-lung-cancer-in-flaura2-phase-iii-trial-3253391?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Tue, 16 May 2023 08:02:00 +0200 AstraZeneca will present new clinical and real-world data in multiple haematological conditions, further demonstrating its ambition to redefine care in haematology at the European Hematology Association (EHA) 2023 Hybrid Congress, 8 to 11 June 2023. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023-3253073?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-showcases-scientific-advances-across-rare-and-malignant-haematological-conditions-at-eha-2023-3253073?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Wed, 10 May 2023 08:01:02 +0200 Ultomiris (ravulizumab) has been approved in the European Union (EU) as the first and only long-acting C5 complement inhibitor for the treatment of adult patients with anti-aquaporin-4 (AQP4) antibody-positive (Ab+) neuromyelitis optica spectrum disorder (NMOSD). https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-3251772?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-approved-in-the-eu-for-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-3251772?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Tue, 09 May 2023 08:02:22 +0200 AstraZeneca’s Farxiga (dapagliflozin) has been approved in the US to reduce the risk of cardiovascular (CV) death, hospitalisation for heart failure (hHF) and urgent heart failure (HF) visits in adults with HF. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/farxiga-extended-in-the-us-to-reduce-risk-of-cardiovascular-death-and-hospitalisation-for-heart-failure-to-a-broader-range-of-patients-3251456?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/farxiga-extended-in-the-us-to-reduce-risk-of-cardiovascular-death-and-hospitalisation-for-heart-failure-to-a-broader-range-of-patients-3251456?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Mon, 08 May 2023 08:01:21 +0200 Koselugo (selumetinib) has been approved in China for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in paediatric patients with neurofibromatosis type 1 (NF1) aged three years and above. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas-3251092?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/koselugo-approved-in-china-for-paediatric-patients-with-neurofibromatosis-type-1-and-plexiform-neurofibromas-3251092?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Sat, 29 Apr 2023 08:00:14 +0200 The Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) has recognised a favourable benefit risk profile for AstraZeneca and MSD’s Lynparza (olaparib) plus abiraterone and prednisone or prednisolone for the treatment of adult patients with BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC) based on the PROpel Phase III trial. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/update-on-fda-advisory-committee-vote-on-lynparza-plus-abiraterone-for-metastatic-castration-resistant-prostate-cancer-3249586?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/update-on-fda-advisory-committee-vote-on-lynparza-plus-abiraterone-for-metastatic-castration-resistant-prostate-cancer-3249586?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Thu, 27 Apr 2023 08:01:42 +0200 Stark start på året med stabila totala intäkter och en tillväxt på 15% exklusive covid-19-läkemedel https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazenecas-resultatrapport-foer-foersta-kvartalet-2023-3248995?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazenecas-resultatrapport-foer-foersta-kvartalet-2023-3248995?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Mon, 24 Apr 2023 13:01:56 +0200 Detailed results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed AstraZeneca and Ionis’ eplontersen met all co-primary endpoints and secondary endpoints at 66 weeks versus an external placebo group. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement-in-all-measures-of-disease-and-quality-of-life-through-66-weeks-3247899?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/neuro-ttransform-phase-iii-results-presented-at-aan-showed-eplontersen-demonstrated-consistent-and-sustained-improvement-in-all-measures-of-disease-and-quality-of-life-through-66-weeks-3247899?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Sun, 16 Apr 2023 18:06:30 +0200 Results presented at AACR 2023 found that four times as many patients treated with Imfinzi plus chemotherapy before surgery achieved pathologic complete response versus those treated with neoadjuvant chemotherapy alone. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-by-32-percent-in-resectable-non-small-cell-lung-cancer-in-the-aegean-phase-iii-trial-3246192?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/imfinzi-based-treatment-before-and-after-surgery-reduced-the-risk-of-disease-recurrence-progression-events-or-death-by-32-percent-in-resectable-non-small-cell-lung-cancer-in-the-aegean-phase-iii-trial-3246192?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Fri, 14 Apr 2023 18:01:23 +0200 AstraZeneca will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Association for Cancer Research (AACR) Annual Meeting, 14 to 19 April 2023. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr-3245978?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/astrazeneca-advances-its-pipeline-and-highlights-progress-in-immuno-oncology-adcs-cell-therapy-and-epigenetics-at-aacr-3245978?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Fri, 14 Apr 2023 08:02:19 +0200 AstraZeneca will highlight new data across its Vaccines and Immune Therapies portfolio at the 33rd European Congress of Clinical Microbiology & Infectious Diseases (ECCMID), 15 – 18 April 2023, reinforcing its ambition to provide long-lasting immunity for millions of people globally. The company will present 15 abstracts, including four oral presentations, at the event. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies-3245966?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/eccmid-data-reinforces-astrazenecas-commitment-to-transform-protection-for-the-most-vulnerable-by-advancing-science-in-vaccines-and-immune-therapies-3245966?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Tue, 11 Apr 2023 08:01:10 +0200 https://www.mynewsdesk.com/se/astrazeneca/pressreleases/update-to-contractual-arrangements-between-astrazeneca-swedish-orphan-biovitrum-ab-and-sanofi-3245166?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/update-to-contractual-arrangements-between-astrazeneca-swedish-orphan-biovitrum-ab-and-sanofi-3245166?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Wed, 05 Apr 2023 08:02:18 +0200 Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/lynparza-and-imfinzi-combination-improved-progression-free-survival-in-newly-diagnosed-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-duo-o-phase-iii-trial-3244692?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/lynparza-and-imfinzi-combination-improved-progression-free-survival-in-newly-diagnosed-patients-with-advanced-ovarian-cancer-without-tumour-brca-mutations-in-duo-o-phase-iii-trial-3244692?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Mon, 03 Apr 2023 08:03:01 +0200 Ultomiris (ravulizumab) has been recommended for marketing authorisation in the European Union (EU) for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are anti-aquaporin-4 (AQP4) antibody positive (Ab+). https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-3244079?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/ultomiris-recommended-for-approval-in-the-eu-by-chmp-for-the-treatment-of-adults-with-neuromyelitis-optica-spectrum-disorder-nmosd-3244079?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Thu, 30 Mar 2023 08:03:48 +0200 AstraZeneca has completed an exclusive global license agreement with KYM Biosciences Inc. for CMG901, a potential first-in-class antibody drug conjugate (ADC) targeting Claudin 18.2, a promising therapeutic target in gastric cancers. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/license-agreement-with-kym-biosciences-for-cmg901-a-claudin-18-dot-2-antibody-drug-conjugate-completed-3243302?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/license-agreement-with-kym-biosciences-for-cmg901-a-claudin-18-dot-2-antibody-drug-conjugate-completed-3243302?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB Mon, 27 Mar 2023 08:01:15 +0200 Positive high-level results from the NEURO-TTRansform Phase III trial in patients with hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) showed eplontersen met its co-primary endpoints through 66 weeks. The results were consistent with the positive 35-week findings announced in June 2022. https://www.mynewsdesk.com/se/astrazeneca/pressreleases/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-through-66-weeks-3242287?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease https://www.mynewsdesk.com/se/astrazeneca/pressreleases/eplontersen-demonstrated-sustained-benefit-in-phase-iii-trial-for-hereditary-transthyretin-mediated-amyloid-polyneuropathy-attrv-pn-through-66-weeks-3242287?utm_source=rss&utm_medium=rss&utm_campaign=Subscription&utm_content=pressrelease AstraZeneca AB